Our Partners

Ovid is actively evaluating and forming partnerships and alliances with companies, clinicians, patient organizations and academic scientists.

Collaborations are core to the company’s strategy to expand and enhance its capabilities, as well as provide better medicines for patients.

For more information or inquiries on collaborations and partnerships, please contact partnering@ovidrx.com.

Developing BoldMedicine to Transform the Lives of People with Rare Neurological Diseases

Corporate Alliances

Takeda

In January 2017, Takeda and Ovid Therapeutics Inc. announced an innovative clinical development and commercialization collaboration for TAK-935/OV935 in rare pediatric epilepsies.

Lundbeck

In April 2015, Lundbeck and Ovid Therapeutics Inc. announced an exclusive global licensing agreement for OV101.

Patient Organizations

Ovid is collaborating with patient advocacy groups and foundations.